These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
819 related articles for article (PubMed ID: 35351582)
1. Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: A 2022 update. Boukouris AE; Theochari M; Stefanou D; Papalambros A; Felekouras E; Gogas H; Ziogas DC Crit Rev Oncol Hematol; 2022 May; 173():103663. PubMed ID: 35351582 [TBL] [Abstract][Full Text] [Related]
2. Complete Metabolic Response to Combined Immune Checkpoint Inhibition after Progression of Metastatic Colorectal Cancer on Pembrolizumab: A Case Report. Krekeler C; Wethmar K; Mikesch JH; Kerkhoff A; Menck K; Lenz G; Schildhaus HU; Wessolly M; Hoffmann MW; Pascher A; Asmus I; Wardelmann E; Bleckmann A Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569431 [TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities. Zhang X; Wu T; Cai X; Dong J; Xia C; Zhou Y; Ding R; Yang R; Tan J; Zhang L; Zhang Y; Wang Y; Dong C; Li Y Front Immunol; 2022; 13():795972. PubMed ID: 35371084 [TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Blockade Therapy in Patients With Colorectal Cancer Harboring Microsatellite Instability/Mismatch Repair Deficiency in 2022. André T; Cohen R; Salem ME Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-9. PubMed ID: 35471834 [TBL] [Abstract][Full Text] [Related]
5. Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer. Trojan J; Stintzing S; Haase O; Koch C; Ziegler P; Demes M; Jelas I Oncologist; 2021 Dec; 26(12):e2110-e2114. PubMed ID: 34431576 [TBL] [Abstract][Full Text] [Related]
6. Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden. Quintanilha JCF; Graf RP; Fisher VA; Oxnard GR; Ellis H; Panarelli N; Lin DI; Li G; Huang RSP; Ross JS; Myer PA; Klempner SJ JAMA Netw Open; 2023 Jan; 6(1):e2252244. PubMed ID: 36689222 [TBL] [Abstract][Full Text] [Related]
7. Immunotherapy and metastatic colorectal cancers with microsatellite instability or mismatch repair deficiency. Cohen R; Pellat A; Boussion H; Svrcek M; Lopez-Trabada D; Trouilloud I; Afchain P; André T Bull Cancer; 2019 Feb; 106(2):137-142. PubMed ID: 30327191 [TBL] [Abstract][Full Text] [Related]
8. Clinical Development of Immunotherapy for Deficient Mismatch Repair Colorectal Cancer. Thomas J; Leal A; Overman MJ Clin Colorectal Cancer; 2020 Jun; 19(2):73-81. PubMed ID: 32173280 [TBL] [Abstract][Full Text] [Related]
9. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. André T; Lonardi S; Wong KYM; Lenz HJ; Gelsomino F; Aglietta M; Morse MA; Van Cutsem E; McDermott R; Hill A; Sawyer MB; Hendlisz A; Neyns B; Abdullaev S; Memaj A; Lei M; Dixon M; Kopetz S; Overman MJ Ann Oncol; 2022 Oct; 33(10):1052-1060. PubMed ID: 35764271 [TBL] [Abstract][Full Text] [Related]